Fennec Pharmaceuticals Inc. (FRX.TO)
CAD 8.12
(-6.34%)
CAD 8.12
(-6.34%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -12.77 Million USD | 43.46% |
| 2022 | -22.58 Million USD | -31.16% |
| 2021 | -17.22 Million USD | 3.7% |
| 2020 | -17.88 Million USD | -37.48% |
| 2019 | -13 Million USD | -24.98% |
| 2018 | -10.4 Million USD | -49.75% |
| 2017 | -6.95 Million USD | -142.11% |
| 2016 | -2.87 Million USD | -51.9% |
| 2015 | -1.89 Million USD | 34.31% |
| 2014 | -2.87 Million USD | -48.99% |
| 2013 | -1.93 Million USD | 46.66% |
| 2012 | -3.62 Million USD | -5.29% |
| 2011 | -3.43 Million USD | 25.33% |
| 2010 | -4.6 Million USD | -43.16% |
| 2009 | -3.21 Million USD | 76.84% |
| 2008 | -13.88 Million USD | 2.14% |
| 2007 | -14.19 Million USD | 25.56% |
| 2006 | -19.06 Million USD | -3.91% |
| 2005 | -18.34 Million USD | 0.0% |
| 2003 | -9.42 Million USD | -39.69% |
| 2002 | -6.74 Million USD | -66.91% |
| 2001 | -4.04 Million USD | -52.56% |
| 2000 | -2.64 Million USD | -64.97% |
| 1999 | -1.6 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -5.03 Million USD | -136.67% |
| 2024 Q1 | 13.74 Million USD | 855.94% |
| 2023 Q3 | -1.01 Million USD | 78.2% |
| 2023 Q1 | -5.34 Million USD | 12.93% |
| 2023 Q2 | -4.66 Million USD | 12.65% |
| 2023 Q4 | -1.81 Million USD | -78.76% |
| 2023 FY | -12.77 Million USD | 43.46% |
| 2022 Q4 | -6.13 Million USD | 22.33% |
| 2022 Q1 | -3.54 Million USD | 15.71% |
| 2022 FY | -22.58 Million USD | -31.16% |
| 2022 Q3 | -7.89 Million USD | -57.7% |
| 2022 Q2 | -5 Million USD | -41.26% |
| 2021 Q2 | -3.92 Million USD | 20.37% |
| 2021 Q3 | -4.17 Million USD | -6.45% |
| 2021 Q4 | -4.2 Million USD | -0.81% |
| 2021 FY | -17.22 Million USD | 3.7% |
| 2021 Q1 | -4.92 Million USD | -47.13% |
| 2020 Q3 | -5.85 Million USD | -20.93% |
| 2020 Q1 | -3.83 Million USD | -4.98% |
| 2020 Q4 | -3.34 Million USD | 42.89% |
| 2020 FY | -17.88 Million USD | -37.48% |
| 2020 Q2 | -4.84 Million USD | -26.34% |
| 2019 Q1 | -2.68 Million USD | 13.69% |
| 2019 Q3 | -1.86 Million USD | 61.29% |
| 2019 Q2 | -4.81 Million USD | -79.59% |
| 2019 FY | -13 Million USD | -24.98% |
| 2019 Q4 | -3.65 Million USD | -96.08% |
| 2018 Q2 | -2.66 Million USD | -48.8% |
| 2018 Q3 | -2.84 Million USD | -6.87% |
| 2018 Q4 | -3.1 Million USD | -9.02% |
| 2018 Q1 | -1.79 Million USD | 28.79% |
| 2018 FY | -10.4 Million USD | -49.75% |
| 2017 FY | -6.95 Million USD | -142.11% |
| 2017 Q2 | -1.47 Million USD | -91.83% |
| 2017 Q4 | -2.51 Million USD | -15.05% |
| 2017 Q3 | -2.18 Million USD | -47.8% |
| 2017 Q1 | -771 Thousand USD | 32.72% |
| 2016 Q4 | -1.14 Million USD | -103.19% |
| 2016 FY | -2.87 Million USD | -51.9% |
| 2016 Q1 | -454 Thousand USD | 17.6% |
| 2016 Q3 | -564 Thousand USD | 20.23% |
| 2016 Q2 | -707 Thousand USD | -55.73% |
| 2015 Q1 | -452 Thousand USD | 42.86% |
| 2015 Q3 | -338 Thousand USD | 38.43% |
| 2015 Q4 | -551 Thousand USD | -63.02% |
| 2015 Q2 | -549 Thousand USD | -21.46% |
| 2015 FY | -1.89 Million USD | 34.31% |
| 2014 Q1 | -537 Thousand USD | -29.09% |
| 2014 Q4 | -791 Thousand USD | -27.79% |
| 2014 Q2 | -930 Thousand USD | -73.18% |
| 2014 Q3 | -619 Thousand USD | 33.44% |
| 2014 FY | -2.87 Million USD | -48.99% |
| 2013 Q3 | -51 Thousand USD | 94.5% |
| 2013 Q4 | -416 Thousand USD | -715.69% |
| 2013 FY | -1.93 Million USD | 46.66% |
| 2013 Q2 | -927 Thousand USD | -72.63% |
| 2013 Q1 | -537 Thousand USD | 52.18% |
| 2012 Q1 | -616 Thousand USD | 31.71% |
| 2012 Q3 | -630 Thousand USD | 49.6% |
| 2012 Q4 | -1.12 Million USD | -78.25% |
| 2012 FY | -3.62 Million USD | -5.29% |
| 2012 Q2 | -1.25 Million USD | -102.92% |
| 2011 FY | -3.43 Million USD | 25.33% |
| 2011 Q4 | -902 Thousand USD | 4.45% |
| 2011 Q3 | -944 Thousand USD | -65.03% |
| 2011 Q2 | -572 Thousand USD | 43.98% |
| 2011 Q1 | -1.02 Million USD | -25.12% |
| 2010 Q1 | -366 Thousand USD | -1089.19% |
| 2010 FY | -4.6 Million USD | -43.16% |
| 2010 Q4 | -816 Thousand USD | 11.01% |
| 2010 Q3 | -917 Thousand USD | -207366.06% |
| 2010 Q2 | -442.00 USD | 99.88% |
| 2009 FY | -3.21 Million USD | 76.84% |
| 2009 Q4 | 37 Thousand USD | 110.88% |
| 2009 Q3 | -340 Thousand USD | 64.62% |
| 2009 Q2 | -961 Thousand USD | 50.77% |
| 2009 Q1 | -1.95 Million USD | 26.06% |
| 2008 Q2 | -3.51 Million USD | 20.85% |
| 2008 Q1 | -4.43 Million USD | -39.5% |
| 2008 FY | -13.88 Million USD | 2.14% |
| 2008 Q4 | -2.64 Million USD | 19.98% |
| 2008 Q3 | -3.29 Million USD | 6.04% |
| 2007 FY | -14.19 Million USD | 25.56% |
| 2007 Q4 | -3.18 Million USD | 7.99% |
| 2007 Q1 | -4.11 Million USD | 23.46% |
| 2007 Q2 | -3.43 Million USD | 16.43% |
| 2007 Q3 | -3.45 Million USD | -0.49% |
| 2006 Q4 | -5.37 Million USD | -1.19% |
| 2006 FY | -19.06 Million USD | -3.91% |
| 2006 Q3 | -5.31 Million USD | -17.47% |
| 2006 Q2 | -4.52 Million USD | -17.45% |
| 2006 Q1 | -3.85 Million USD | 25.78% |
| 2005 Q3 | -4.8 Million USD | 2.82% |
| 2005 Q2 | -4.94 Million USD | -44.58% |
| 2005 Q1 | -3.41 Million USD | 0.0% |
| 2005 Q4 | -5.18 Million USD | -8.08% |
| 2005 FY | -18.34 Million USD | 0.0% |
| 2004 Q1 | -2.7 Million USD | -25.35% |
| 2004 Q3 | -3.15 Million USD | -8.71% |
| 2004 Q2 | -2.9 Million USD | -7.27% |
| 2003 Q2 | -2.34 Million USD | -23.52% |
| 2003 FY | -9.42 Million USD | -39.69% |
| 2003 Q4 | -2.16 Million USD | -31.92% |
| 2003 Q3 | -1.63 Million USD | 30.21% |
| 2003 Q1 | -1.89 Million USD | -61.39% |
| 2002 Q3 | -1.14 Million USD | 23.24% |
| 2002 Q2 | -1.49 Million USD | -64.08% |
| 2002 Q1 | -909.61 Thousand USD | -30.83% |
| 2002 FY | -6.74 Million USD | -66.91% |
| 2002 Q4 | -1.17 Million USD | -2.75% |
| 2001 Q2 | -2.64 Million USD | -417585523.13% |
| 2001 FY | -4.04 Million USD | -52.56% |
| 2001 Q4 | -695.25 Thousand USD | 27.07% |
| 2001 Q3 | -953.32 Thousand USD | 64.01% |
| 2001 Q1 | 0.63 USD | 100.0% |
| 2000 FY | -2.64 Million USD | -64.97% |
| 2000 Q3 | 0.67 USD | 0.0% |
| 2000 Q4 | -558.82 Thousand USD | -83985942.68% |
| 1999 FY | -1.6 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Appili Therapeutics Inc. | -8.05 Million CAD | -58.642% |
| Eupraxia Pharmaceuticals Inc. | -36.89 Million CAD | 65.387% |
| Helix BioPharma Corp. | -9.37 Million CAD | -36.282% |
| Microbix Biosystems Inc. | -2.73 Million CAD | -366.703% |
| Medicenna Therapeutics Corp. | -19.66 Million CAD | 35.051% |
| Satellos Bioscience Inc. | -15.46 Million CAD | 17.409% |
| Oncolytics Biotech Inc. | -33.79 Million CAD | 62.206% |
| Sernova Corp. | -41.13 Million CAD | 68.95% |